#Israel #Ramat Gan #Galmed Pharmaceuticals #Colospan #CG-100

Galmed Pharmaceuticals Restructures Acquisition of Colospan

In a strategic maneuver, Galmed Pharmaceuticals Ltd. has announced a restructuring of its acquisition terms for Colospan Ltd., aiming to enhance both shareholder value and the European commercialization of the CG-100 device. This acquisition not only underscores Galmed's commitment to advancing its gastrointestinal care portfolio but also positions it to address one of the most pressing challenges in colorectal surgeries.

Acquisition Highlights

On June 22, 2026, Galmed completed its acquisition of Colospan, a company known for its innovative medical device solutions, specifically aimed at treating complications associated with colorectal surgeries such as anastomotic leaks and the subsequent need for diverting stomas. Previously entangled in dilutive financial terms involving the issuance of shares, the revised agreement now includes an increased cash payment and a structured earnout tied to clear performance metrics. Rather than issuing $2 million in shares at closure, Galmed will pay an additional $800,000 in cash and has implemented a performance-based earnout of up to $2 million that is contingent upon net sales revenue performance.

This new framework is designed to protect current shareholders from the dilution of their investments, a move that undoubtedly reflects Galmed's strategic foresight in maintaining financial stability while expanding its core products. The earnout will roll out starting in Q3 2027, linking pay to specific sales targets of CG-100.

The CG-100 Device

CG-100 is anticipated to reshape the landscape of colorectal surgery. As a less invasive intraluminal bypass device, it is engineered to protect colorectal anastomoses, with clinical trials demonstrating significant safety and efficacy. Across four clinical studies conducted from 2014 to 2024 in Europe and Israel, an impressive 90% of treated patients have avoided the creation of stomas, showcasing the device's ability to mitigate the risks typically associated with colorectal procedures. Notably, the device has recorded 0% mortality and minimal adverse events compared to traditional stoma procedures.

Real-World Impact

With projections indicating that the device could generate revenue in 2026, Galmed is preparing to present real-world data from CG-100 users to the FDA. This step is crucial for supporting ongoing pivotal studies and positioning the device favorably in the market. Galmed's plan aligns well with contemporary trends demanding less invasive surgical options, which are becoming increasingly popular within the medical community.

Long-Term Strategy

CEO Allen Baharaff elaborated on the strategic synergy between Galmed and Colospan during a recent announcement, emphasizing the goal of establishing a unified gastrointestinal platform powered by both Galmed's drug development expertise and innovative medical device commercialization. This merger will bolster Galmed's long-term focus on gastrointestinal healthcare, coupling the capabilities of CG-100 with its leading drug candidate, Aramchol, that targets GI-related oncological indications.

By creating this integrated approach, Galmed aims to become a prominent player in the GI medtech and biopharmaceutical sectors. The company is now poised to deliver innovative tools meant to enhance surgical standards and ultimately improve patient outcomes across the globe.

Future Outlook

As Galmed Pharmaceuticals gears up for this pivotal launch and embraces its new acquisition of Colospan, expectations are high for both entities to flourish under the shared goal of advancing treatment methodologies in colorectal care. With solid financial maneuvering and a robust clinical portfolio, Galmed is strategically positioned for a successful future, one that could redefine care standards in its target market.

For more information, Galmed invites interested parties to explore their website at www.galmedpharma.com and learn more about CG-100 and its potential impact in colorectal surgery.

Disclaimer: This article may contain forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those expressed or implied.